NASDAQ:MESO - Mesoblast Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.85
  • Forecasted Upside: 0.25 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$15.81
▲ +2.03 (14.73%)
1 month | 3 months | 12 months
Get New Mesoblast Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MESO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MESO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$15.85
▲ +0.25% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Mesoblast in the last 3 months. The average price target is $15.85, with a high forecast of $20.00 and a low forecast of $12.00. The average price target represents a 0.25% upside from the last price of $15.81.
Buy
The current consensus among 5 investment analysts is to buy stock in Mesoblast. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/2/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/31/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/29/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/27/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/27/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2020HC WainwrightBoost Price TargetBuy$19.00 ➝ $20.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
10/22/2020Royal Bank of CanadaInitiated CoverageSector Perform$12.00Low
i
10/5/2020Maxim GroupLower Price Target$22.00 ➝ $18.00Low
i
Rating by Jason McCarthy at Maxim Group
10/2/2020HC WainwrightLower Price TargetBuy$21.00 ➝ $19.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/14/2020Maxim GroupBoost Price TargetBuy$16.00 ➝ $22.00High
i
Rating by Jason McCarthy at Maxim Group
5/29/2020Maxim GroupInitiated CoverageBuy$16.00High
i
Rating by Jason McCarthy at Maxim Group
5/28/2020LADENBURG THALM/SH SHBoost Price TargetBuy$13.00 ➝ $15.25Low
i
5/28/2020HC WainwrightReiterated RatingPositive ➝ Buy$14.00 ➝ $21.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/27/2020HC WainwrightReiterated RatingBuy$14.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/9/2020HC WainwrightReiterated RatingBuyN/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
2/28/2020Maxim GroupReiterated RatingBuy$16.00Medium
i
2/6/2020HC WainwrightReiterated RatingBuy$14.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/19/2019Dawson JamesInitiated CoverageBuy$14.00Low
i
Rating by Jason Kolbert at Dawson James
11/27/2019Maxim GroupReiterated RatingBuy$16.00Low
i
Rating by Jason McCarthy at Maxim Group
11/26/2019HC WainwrightReiterated RatingBuy$8.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
10/22/2019Cantor FitzgeraldReiterated RatingOverweight$23.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
9/12/2019Maxim GroupReiterated RatingBuy$16.00N/A
i
Rating by Jason McCarthy at Maxim Group
9/10/2019Cantor FitzgeraldSet Price TargetBuy$23.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
9/10/2019OppenheimerSet Price TargetBuy$10.00N/A
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
8/30/2019HC WainwrightSet Price TargetBuy$7.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/30/2019Chardan CapitalSet Price TargetHold$6.00Low
i
Rating by Keay Nakae at Chardan Capital
6/12/2019Maxim GroupReiterated RatingBuy$16.00Low
i
Rating by Jason McCarthy at Maxim Group
6/5/2019HC WainwrightInitiated CoverageBuy$7.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/31/2019Chardan CapitalSet Price TargetHold$6.00Medium
i
Rating by Keay Nakae at Chardan Capital
5/30/2019Maxim GroupInitiated CoverageBuy$16.00Medium
i
Rating by Jason McCarthy at Maxim Group
4/16/2019Maxim GroupReiterated RatingBuyHigh
i
Rating by Jason McCarthy at Maxim Group
2/22/2019HC WainwrightReiterated RatingBuyHigh
i
Rating by S. Ramakanth at HC Wainwright
2/21/2019Maxim GroupReiterated RatingBuy$16.00Medium
i
Rating by Jason McCarthy at Maxim Group
1/31/2019HC WainwrightReiterated RatingBuy ➝ Buy$6.50High
i
Rating by Jason Kolbert at HC Wainwright
12/13/2018OppenheimerSet Price TargetBuy$15.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/26/2018Maxim GroupSet Price TargetBuy$16.00Medium
i
Rating by Jason McCarthy at Maxim Group
11/13/2018HC WainwrightSet Price TargetBuy$17.00High
i
Rating by Jason Kolbert at HC Wainwright
11/12/2018Maxim GroupReiterated RatingBuy$16.00Medium
i
11/12/2018OppenheimerSet Price TargetBuy$15.00Medium
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/11/2018Cantor FitzgeraldSet Price TargetBuy$23.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
10/25/2018HC WainwrightSet Price TargetBuy$17.00Medium
i
Rating by Jason Kolbert at HC Wainwright
10/12/2018Maxim GroupReiterated RatingBuy$16.00Medium
i
10/2/2018HC WainwrightSet Price TargetBuy$17.00High
i
Rating by Jason Kolbert at HC Wainwright
10/1/2018Cantor FitzgeraldSet Price TargetBuy$23.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
9/20/2018Cantor FitzgeraldSet Price TargetBuy$23.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
9/18/2018HC WainwrightSet Price TargetBuy$17.00Low
i
Rating by Jason Kolbert at HC Wainwright
8/30/2018HC WainwrightSet Price TargetBuy$17.00Low
i
Rating by Jason Kolbert at HC Wainwright
8/30/2018Cantor FitzgeraldSet Price TargetBuy$23.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
7/18/2018Maxim GroupBoost Price TargetBuy ➝ Buy$14.00 ➝ $16.00High
i
Rating by Jason McCarthy at Maxim Group
7/17/2018Cantor FitzgeraldSet Price TargetBuy$23.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
7/17/2018HC WainwrightSet Price TargetBuy$17.00High
i
Rating by Jason Kolbert at HC Wainwright
7/2/2018HC WainwrightSet Price TargetBuy$17.00High
i
Rating by Jason Kolbert at HC Wainwright
6/21/2018Cantor FitzgeraldReiterated RatingBuy$23.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
6/7/2018HC WainwrightInitiated CoverageBuy$17.00High
i
Rating by J. Kolbert at HC Wainwright
5/31/2018Cantor FitzgeraldSet Price TargetBuy$23.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
3/29/2018Maxim GroupSet Price TargetBuy$14.00Low
i
Rating by Jason McCarthy at Maxim Group
3/22/2018Credit Suisse GroupDowngradeNeutral ➝ Underperform$6.00Medium
i
3/7/2018Maxim GroupSet Price TargetBuy$14.00Low
i
Rating by Jason Kolbert at Maxim Group
2/28/2018Maxim GroupSet Price TargetBuy$14.00High
i
Rating by Jason Kolbert at Maxim Group
2/27/2018Cantor FitzgeraldSet Price TargetBuy ➝ Buy$20.00 ➝ $23.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
2/22/2018Maxim GroupSet Price TargetBuy$14.00High
i
Rating by Jason Kolbert at Maxim Group
2/21/2018Cantor FitzgeraldSet Price TargetBuy$20.00 ➝ $23.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
1/31/2018Maxim GroupReiterated RatingBuy$14.00Low
i
Rating by Jason Kolbert at Maxim Group
1/16/2018Cantor FitzgeraldSet Price TargetBuy$20.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
12/20/2017OppenheimerSet Price TargetBuy$16.00Low
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/18/2017Maxim GroupSet Price TargetBuy$14.00High
i
Rating by Jason Kolbert at Maxim Group
11/15/2017Maxim GroupSet Price TargetBuy$14.00N/A
i
Rating by Jason McCarthy at Maxim Group
11/14/2017OppenheimerSet Price TargetBuy$16.00N/A
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
9/26/2017Maxim GroupReiterated RatingBuy$14.00Low
i
Rating by Jason McCarthy at Maxim Group
8/31/2017CIBCInitiated CoverageOutperform ➝ Outperform$16.00High
i
8/31/2017OppenheimerInitiated CoverageOutperform$16.00High
i
8/30/2017Maxim GroupSet Price TargetBuy$14.00High
i
Rating by Jason McCarthy at Maxim Group
8/30/2017Cantor FitzgeraldReiterated RatingBuy$20.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
8/23/2017Cantor FitzgeraldReiterated RatingBuyMedium
i
Rating by Elemer Piros at Cantor Fitzgerald
8/16/2017Cantor FitzgeraldSet Price TargetBuy$20.00Medium
i
Rating by E. Piros at Cantor Fitzgerald
8/16/2017Maxim GroupSet Price TargetBuy$14.00High
i
Rating by Jason Kolbert at Maxim Group
7/18/2017Credit Suisse GroupSet Price TargetHold$11.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
6/8/2017Cantor FitzgeraldReiterated RatingOverweightMedium
i
Rating by E. Piros at Cantor Fitzgerald
6/7/2017Cantor FitzgeraldInitiated CoverageBuy ➝ Buy$20.00High
i
5/25/2017Maxim GroupSet Price TargetBuy$14.00Low
i
Rating by Jason McCarthy at Maxim Group
4/11/2017Maxim GroupReiterated RatingBuy$14.00Low
i
Rating by Jason Kolbert at Maxim Group
4/3/2017ScotiabankReiterated RatingHold$8.50Low
i
3/31/2017Maxim GroupReiterated RatingBuy$14.00High
i
3/15/2017Maxim GroupReiterated RatingBuy ➝ Positive$14.00Medium
i
3/7/2017Maxim GroupReiterated RatingBuy$14.00N/A
i
2/27/2017Maxim GroupSet Price TargetBuy$14.00N/A
i
12/6/2016Maxim GroupSet Price TargetBuy$14.00N/A
i
10/6/2016Maxim GroupSet Price TargetBuy$14.00N/A
i
9/6/2016Maxim GroupReiterated RatingBuy$14.00N/A
i
8/16/2016Maxim GroupSet Price TargetBuy$14.00N/A
i
8/9/2016Maxim GroupReiterated RatingBuyN/A
i
7/6/2016Maxim GroupReiterated RatingBuy$14.00N/A
i
Rating by Jason Kolbert at Maxim Group
6/15/2016Credit Suisse GroupDowngradeHoldN/A
i
6/15/2016JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
6/14/2016Credit Suisse GroupDowngradeOutperform ➝ Neutral$10.00 ➝ $5.00N/A
i
6/4/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason Kolbert at Maxim Group
5/10/2016Maxim GroupReiterated RatingBuy$18.00 ➝ $14.00N/A
i
Rating by Jason Kolbert at Maxim Group
3/7/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$9.00 ➝ $10.00N/A
i
Rating by Anupam Rama at JPMorgan Chase & Co.
2/25/2016Chardan CapitalReiterated RatingHoldN/A
i
Rating by Keay Nakae at Chardan Capital
2/22/2016Maxim GroupReiterated RatingBuy$18.00N/A
i
Rating by Jason Kolbert at Maxim Group
2/19/2016Chardan CapitalInitiated CoverageNeutral$5.50N/A
i
2/16/2016Maxim GroupReiterated RatingBuy$18.00N/A
i
1/19/2016Credit Suisse GroupInitiated CoverageOutperform$10.00N/A
i
1/11/2016Maxim GroupReiterated RatingBuy$18.00N/A
i
12/31/2015Maxim GroupLower Price TargetBuy$18.00N/A
i
12/8/2015JPMorgan Chase & Co.Initiated CoverageOverweight$10.00N/A
i
11/24/2015LADENBURG THALM/SH SHReiterated RatingBuyN/A
i
Rating by Kevin Degeeter at LADENBURG THALM/SH SH
(Data available from 11/23/2015 forward)
Mesoblast logo
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Read More

Today's Range

Now: $15.81
$15.00
$15.82

50 Day Range

MA: $11.67
$10.42
$18.59

52 Week Range

Now: $15.81
$3.12
$21.28

Volume

1,095,922 shs

Average Volume

794,068 shs

Market Capitalization

$1.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.87